Ken Griffin Agios Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$41.19 - $49.72 $102,975 - $124,300	-2,500 Reduced 16.45%	12,700 $564,000
Q2 2024 Aug 14, 2024	SELL	$27.55 - $48.83 $424,270 - $751,982	-15,400 Reduced 50.33%	15,200 $655,000
Q1 2024 May 15, 2024	BUY	$21.32 - $34.81 $413,608 - $675,314	19,400 Added 173.21%	30,600 $894,000
Q4 2023 Feb 14, 2024	SELL	$19.97 - $24.53 $79,880 - $98,120	-4,000 Reduced 26.32%	11,200 $249,000
Q3 2023 Nov 14, 2023	BUY	$24.36 - $28.18 $9,744 - $11,272	400 Added 2.7%	15,200 $376,000
Q2 2023 Aug 14, 2023	BUY	$21.38 - $29.19 $226,628 - $309,414	10,600 Added 252.38%	14,800 $419,000
Q1 2023 May 15, 2023	SELL	$21.74 - $30.93 $600,024 - $853,668	-27,600 Reduced 86.79%	4,200 $96,000
Q4 2022 Feb 14, 2023	SELL	$24.81 - $31.52 $873,312 - $1.11 Million	-35,200 Reduced 52.54%	31,800 $892,000
Q3 2022 Nov 14, 2022	BUY	$19.51 - $34.14 $825,273 - $1.44 Million	42,300 Added 171.26%	67,000 $1.9 Million

232

58.1M

403K

469K

Ticker AGIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,818,000
Market Cap $3.26B
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.